IGFBP-4 Expression is Adversely Associated with Lung Cancer Prognosis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Nov 23

PMID 29163706

Citations 15

Authors

Yang Xiao

Shan Zhu

Wen Yin

Xiaofan Liu

Yi Hu

Affiliations

Soon will be listed here.

Abstract

Insulin-like growth factor binding protein-4 (IGFBP-4) was reported to be associated with prognosis in several types of cancer; however, to the best of our knowledge, whether it is correlated with lung cancer has yet to be reported. In the present study, 102 pairs of lung cancer tissues and surrounding non-cancerous tissues (SNCTs) were collected. The IGFBP-4 levels in tissues were detected with immunohistochemistry. The relevance of IGFBP-4 to the survival of patients was assessed. The IGFBP-4 gene was knocked down, and its function in the proliferation of lung cancer cells was measured. The percentage of lung cancer tissues with higher IGFBP-4 expression than SNCTs (51.9%) was increased compared with the percentage with similar (11.76%) or lower (36.27%) IGFBP-4 expression. Patients with higher IGFBP-1 expression exhibited a shorter median survival time. IGFBP-1 was associated with metastasis, lung cancer stages and malignancy, but not with age, sex or tumor size. Lung cancer cells with stably knocked down IGFBP-4 showed an inhibitory proliferation rate. The present study identified that IGFBP-4 was adversely associated with the prognosis of lung cancer patients. IGFBP-4 knockdown prohibited lung cancer cell growth. The present study provides a potential marker for lung cancer diagnosis and a possible target for lung cancer therapy.

Citing Articles

Deciphering smooth muscle cell heterogeneity in atherosclerotic plaques and constructing model: a multi-omics approach with focus on KLF15/IGFBP4 axis.

Peng Z, Kan Q, Wang K, Deng T, Wang S, Wu R BMC Genomics. 2024; 25(1):490.

PMID: 38760675 PMC: 11102212. DOI: 10.1186/s12864-024-10379-y.

Organ Boundary Circuits Regulate Sox9+ Alveolar Tuft Cells During Post-Pneumonectomy Lung Regeneration.

Obata T, Mizoguchi S, Greaney A, Adams T, Yuan Y, Edelstein S bioRxiv. 2024; .

PMID: 38260691 PMC: 10802449. DOI: 10.1101/2024.01.07.574469.

The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.

Chen W, Hu L, Lu X, Wang X, Zhao C, Guo C Breast Cancer Res Treat. 2023; 201(3):353-366.

PMID: 37433992 PMC: 10460732. DOI: 10.1007/s10549-023-07028-5.

A bioinformatic study of IGFBPs in glioma regarding their diagnostic, prognostic, and therapeutic prediction value.

Liu H, Tang T Am J Transl Res. 2023; 15(3):2140-2155.

PMID: 37056850 PMC: 10086936.

IGFBP-6 Network in Chronic Inflammatory Airway Diseases and Lung Tumor Progression.

Venuto S, Coda A, Gonzalez-Perez R, Laselva O, Tolomeo D, Storlazzi C Int J Mol Sci. 2023; 24(5).

PMID: 36902237 PMC: 10003725. DOI: 10.3390/ijms24054804.

References

MELLORS R . The application of labeled antibody technics in studying cell antigens. Cancer Res. 1968; 28(7):1372-81. View

Naujokat C, Steinhart R . Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012; 2012:950658. PMC: 3516046. DOI: 10.1155/2012/950658. View

Pine S, Marshall B, Varticovski L . Lung cancer stem cells. Dis Markers. 2008; 24(4-5):257-66. PMC: 3850541. DOI: 10.1155/2008/396281. View

Shimasaki S, Shimonaka M, Zhang H, Ling N . Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem. 1991; 266(16):10646-53. View

Yang Y, Xu H, Huang W, Ding M, Xiao J, Yang D . Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. J Cell Mol Med. 2015; 19(5):915-23. PMC: 4420595. DOI: 10.1111/jcmm.12397. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Diehl D, Lahm H, Wolf E, Bauersachs S . Transcriptome analysis of a human colorectal cancer cell line shows molecular targets of insulin-like growth factor-binding protein-4 overexpression. Int J Cancer. 2004; 113(4):588-99. DOI: 10.1002/ijc.20580. View

Mosig R, Lobl M, Senturk E, Shah H, Cohen S, Chudin E . IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. J Ovarian Res. 2012; 5(1):3. PMC: 3271973. DOI: 10.1186/1757-2215-5-3. View

10.

Ponten F, Jirstrom K, Uhlen M . The Human Protein Atlas--a tool for pathology. J Pathol. 2008; 216(4):387-93. DOI: 10.1002/path.2440. View

11.

Chen K, Huang Y, Chen J . Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013; 34(6):732-40. PMC: 3674516. DOI: 10.1038/aps.2013.27. View

12.

Lu W, Li Y . Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem. 2014; 115(10):1799-807. PMC: 4134741. DOI: 10.1002/jcb.24850. View

13.

Tang Q, Zhao Z, Li J, Liang Y, Yin J, Zou C . Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011; 311(1):113-21. DOI: 10.1016/j.canlet.2011.07.016. View

14.

Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R . Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659. PMC: 4892125. DOI: 10.1016/j.cell.2009.06.034. View

15.

Dhaheri Y, Attoub S, Arafat K, AbuQamar S, Eid A, Al Faresi N . Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation. Biochim Biophys Acta. 2013; 1830(4):3121-35. DOI: 10.1016/j.bbagen.2013.01.010. View

16.

Resham K, Patel P, Thummuri D, Guntuku L, Shah V, Bambal R . Preclinical drug metabolism and pharmacokinetics of salinomycin, a potential candidate for targeting human cancer stem cells. Chem Biol Interact. 2015; 240:146-52. DOI: 10.1016/j.cbi.2015.08.007. View

17.

Kopp F, Hermawan A, Oak P, Herrmann A, Wagner E, Roidl A . Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer. 2014; 13:16. PMC: 3909296. DOI: 10.1186/1476-4598-13-16. View

18.

Durai R, Davies M, Yang W, Yang S, Seifalian A, Goldspink G . Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol. 2006; 28(6):1317-25. View

19.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

20.

Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C . Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem. 1995; 270(35):20424-31. DOI: 10.1074/jbc.270.35.20424. View